HMGB1 secretion during cervical carcinogenesis promotes the acquisition of a tolerogenic functionality by plasmacytoid dendritic cells

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 345-358

  Demoulin, Stéphanie ^a   Herfs, Michael ^a   Somja, Joan ^b   Roncarati, Patrick ^a   Delvenne, Philippe ^b   Hubert, Pascale ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

cervical cancers; HMGB1; plasmacytoid dendritic cells; tolerogenicity; Treg cells

Indexed keywords

ALPHA INTERFERON; CHEMERIN; CPG OLIGODEOXYNUCLEOTIDE; HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR 9; CHEMERIN, HUMAN; CHEMOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HMGB1 PROTEIN, HUMAN;

ARTICLE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FOXP3+ REGULATORY T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; KERATINOCYTE; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; COCULTURE; CONFOCAL MICROSCOPY; DENDRITIC CELL; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UTERINE CERVIX;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CERVIX UTERI; CHEMOKINES; COCULTURE TECHNIQUES; DENDRITIC CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; KERATINOCYTES; MICROSCOPY, CONFOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 9; TUMOR MICROENVIRONMENT;

EID: 84929287828     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29389     Document Type: Article

References (54)

1. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283: 1031-7.
2. Herfs M, Hubert P, Moutschen M, et al. Mucosal junctions: open doors to HPV and HIV infections? Trends Microbiol 2011; 19: 114-20.
3. Herfs M, Hubert P, Kholod N, et al. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am J Pathol 2008; 172: 1391-402.
4. Herman L, Hubert P, Caberg JH, et al. MIP3 alpha stimulates the migration of Langerhans cells in models of human papillomavirus (HPV)-associated (pre)neoplastic epithelium. Cancer Immunol Immunother 2007; 56: 1087-96.
5. Colonna M, Trinchieri G, Liu YJ., Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-26.
6. Demoulin S, Herfs M, Delvenne P, et al. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol 2013; 93: 343-52.
7. von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 437-48.
8. Shao X, Liu C., Influence of IFN-alpha and IFN-gamma on lymphangiogenesis. J Interferon Cytokine Res 2006; 26: 568-74.
9. U'Ren L, Guth A, Kamstock D, et al. Type I interferons inhibit the generation of tumor-associated macrophages. Cancer Immunol Immunother 2010; 59: 587-98.
10. Liang S, Wei H, Sun R, et al. IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 2003; 23: 190-9.
11. Sisirak V, Faget J, Gobert M, et al. Impaired IFN-a production by plasmacytoid dendritic cells favors regulatory T cell expansion and contributes to breast cancer progression. Cancer Res 2012; 72: 5188-97.
12. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64: 5535-8.
13. Sawant A, Hensel JA, Chanda D, et al. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J Immunol 2012; 189: 4258-65.
14. Jensen TO, Schmidt H, Moller HJ, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2011; 118: 2476-85.
15. Treilleux I, Blay JY, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10: 7466-74.
16. Labidi-Galy SI, Treilleux I, Goddard-Leon S, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 2012; 1: 380-2.
17. Scaffidi P, Misteli T, Bianchi ME., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
18. Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506-15.
19. Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995-1001.
20. Kang R, Zhang Q, Zeh HJ, III, et al. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013; 19: 4046-57.
21. Wild CA, Bergmann C, Fritz G, et al. HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol 2012; 24: 485-94.
22. Kusume A, Sasahira T, Luo Y, et al. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 2009; 76: 155-62.
23. Popovic PJ, DeMarco R, Lotze MT, et al. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol 2006; 177: 8701-7.
24. Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J 2009; 50: 455-64.
25. Skrzeczynska-Moncznik J, Wawro K, Stefanska A, et al. Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. Biochem Biophys Res Commun 2009; 380: 323-7.
26. Detry C, Waltregny D, Quatresooz P, et al. Detection of bone sialoprotein in human (pre)neoplastic lesions of the uterine cervix. Calcif Tissue Int 2003; 73: 9-14.
27. Demoulin S, Roncarati P, Delvenne P, et al. Production of large numbers of plasmacytoid dendritic cells with functional activities from CD34(+) hematopoietic progenitor cells: use of interleukin-3. Exp Hematol 2012; 40: 268-78.
28. Guo X, Jie Y, Ren D, et al. In vitro-expanded CD4(+)CD25(high)Foxp3(+) regulatory T cells controls corneal allograft rejection. Hum Immunol 2012; 73: 1061-7.
29. Hippen KL, Merkel SC, Schirm DK, et al. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant 2011; 11: 1148-57.
30. Vermi W, Riboldi E, Wittamer V, et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med 2005; 201: 509-15.
31. Herfs M, Hubert P, Delvenne P., Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation? Trends Mol Med 2009; 15: 245-53.
32. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339-46.
33. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003; 200: 255-68.
34. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-87.
35. Le Mercier I, Poujol D, Sanlaville A, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013; 73: 4629-40.
36. Watkins SK, Zhu Z, Riboldi E, et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest 2011; 121: 1361-72.
37. Bellone G, Carbone A, Smirne C, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol 2006; 177: 3448-60.
38. Labidi-Galy SI, Sisirak V, Meeus P, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71: 5423-34.
39. Kirkwood J., Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002; 29: 18-26.
40. Ferrantini M, Capone I, Belardelli F., Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884-93.
41. Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6: 722-9.
42. Middel P, Brauneck S, Meyer W, et al. Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma. BMC Cancer 2010; 10: 578.
43. Faget J, Bendriss-Vermare N, Gobert M, et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 2012; 72: 6130-41.
44. Jaafar F, Righi E, Lindstrom V, et al. Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol 2009; 175: 1525-35.
45. Herfs M, Herman L, Hubert P, et al. High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol Immunother 2009; 58: 603-14.
46. Nakanishi M, Rosenberg DW., Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 2013; 35: 123-37.
47. Bekeredjian-Ding I, Schafer M, Hartmann E, et al. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 2009; 128: 439-50.
48. Power CA, Church DJ, Meyer A, et al. Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells. J Exp Med 1997; 186: 825-35.
49. Tang D, Kang R, Zeh HJ, III, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-40.
50. Wild CA, Brandau S, Lotfi R, et al. HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 2012.
51. Kang HJ, Lee H, Choi HJ, et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest 2009; 89: 948-59.
52. Lenz P, Lowy DR, Schiller JT., Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol 2005; 35: 1548-56.
53. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-9.
54. Ries M, Schuster P, Thomann S, et al. Identification of novel oligonucleotides from mitochondrial DNA that spontaneously induce plasmacytoid dendritic cell activation. J Leukoc Biol 2013; 94: 123-35.